Invivyd (IVVD) Earnings Date & Reports

Key Takeaways

• Invivyd is expected to report its third-quarter 2026 results in early-to-mid November, with consensus estimates calling for a loss of roughly $0.11 per share on revenue near $15 million.
• Investors will be watching whether net product revenue for PEMGARDA, the company's COVID-19 prevention antibody, sustains its momentum after growing 22% year over year in the first quarter.
• The pivotal DECLARATION study of lead pipeline candidate VYD2311 is the central watch item, with topline data anticipated around the Q3 2026 timeframe.
• Elevated research and development (R&D) spending tied to clinical trials has widened quarterly losses and remains a key swing factor for the bottom line.
• For more information on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, you can explore additional pages dedicated to each topic.
• To discover data-driven trade ideas across the broader market, consider exploring Trending AI Robots.

Earnings Context and Why It Matters

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company focused on antibody-based protection against serious viral diseases, beginning with SARS-CoV-2, the virus that causes COVID-19. The company's commercial product, PEMGARDA (pemivibart), is a monoclonal antibody (mAb) used for pre-exposure prophylaxis, or prevention before exposure, of COVID-19 in certain immunocompromised adults. The upcoming report carries heightened significance because the company is simultaneously trying to grow its only marketed product while advancing VYD2311, a next-generation intramuscular antibody candidate, through a pivotal Phase 3 trial. Prior quarters have shown steady revenue gains paired with widening losses, so investors will look for evidence that commercial momentum is translating toward a more sustainable financial path.

Earnings Expectations

Analysts expect Invivyd to report a net loss of approximately $0.11 per share for the third quarter of 2026, with consensus revenue near $15.0 million, according to market data aggregators. Estimates vary modestly across sources, with some pointing to a per-share loss closer to $0.13 to $0.14 and revenue in the $15.0 million to $15.6 million range. For comparison, in the third quarter of 2025 the company reported a loss of $0.06 per share on revenue of $13.13 million, meaning the consensus implies notable revenue growth alongside a wider per-share loss year over year.

Recent history offers caution. In the second quarter of 2026, Invivyd posted a loss of $0.14 per share and revenue of $14.29 million, both missing consensus, as heavy spending on the DECLARATION clinical program weighed on results. The company has beaten earnings per share (EPS) estimates in only a handful of its recent quarters, making cost discipline and clinical spending a central focus heading into this print.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable criteria such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending stocks, and breakout candidates more efficiently than manual screening, giving investors a faster way to identify opportunities that match their strategy. Whether you are tracking a specific sector or scanning broadly for momentum, the AI Screener can help you refine your watchlist with data-backed insights.

Market Reaction and Investor Sentiment

Sentiment heading into the report is cautious. Invivyd shares have struggled in 2026, trading well below their 52-week highs and near lower levels of their range, reflecting investor uncertainty about both the durability of PEMGARDA demand and the heavy costs of the VYD2311 development program. The stock has also shown sensitivity to earnings misses in the past, with prior shortfalls tied to revenue and EPS estimates preceding share declines. Heading into this update, the market's attention is split between the quarterly financials and any commentary or data on VYD2311, which many view as the more consequential long-term driver for the company.

Forward Outlook and Key Factors to Monitor

The single most important catalyst for Invivyd is the progress of VYD2311. The candidate is being evaluated in the DECLARATION pivotal study, and topline data has been anticipated around the third quarter of 2026. Any readout or updated timing on this trial could have a larger impact on the share price than the quarterly numbers themselves.

On the commercial side, investors should monitor PEMGARDA's revenue trajectory and whether the company can keep growing sales amid declining broader vaccine utilization. Management has argued that SARS-CoV-2 remains an ever-present threat with periodic waves, which could support steadier demand than a typical seasonal respiratory product.

Finally, watch the expense line. Research and development spending has surged as the company funds its clinical programs, and selling, general and administrative costs have also risen ahead of a potential VYD2311 launch. Invivyd's cash position remains an important buffer, and investors will look for signs that spending normalizes once key trials conclude. As always, no single quarter defines the story, but this report and its accompanying commentary could sharpen the market's view of both the near-term financial path and the long-term pipeline opportunity.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations